PRDM9

Histone-lysine N-methyltransferase PRDM9 · Q9NQV7 · PRDM9 on Sugi Atlas →

4 patent compounds predicted against PRDM9, 2 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30797918 SCHEMBL30797918 1.00 1/20
SCHEMBL21186191 SCHEMBL21186191 0.40 1/20

Clinical trials — most relevant to PRDM9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer PHASE1/PHASE2RECRUITING
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT PHASE2UNKNOWN
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI) nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Danish TURNER Cryopreservation Study nanRECRUITING
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders nanENROLLING_BY_INVITATION
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16 nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
H19 in Acute Lymphoblastic Leukemia. nanUNKNOWN
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks nanRECRUITING
Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment nanCOMPLETED
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Diet-Induced Changes in GEnetic Material nanRECRUITING
Scottish Advanced Fetal Research Study nanRECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PRDM9 binder may also engage these)

ProteinNameSimilarity
Q96EQ9 1.000 Q96EQ9 →
P0C6Y7 0.994 P0C6Y7 →
Q6P1L6 0.983 Q6P1L6 →
Q96JC4 0.982 Q96JC4 →
Q15937 0.982 Q15937 →
P51814 0.981 P51814 →
P0CJ79 0.980 P0CJ79 →
Q08ER8 0.980 Q08ER8 →
Q86XN6 0.980 Q86XN6 →
P10072 0.979 P10072 →
Q96NI8 0.979 Q96NI8 →
Q6ZN06 0.979 Q6ZN06 →
Q3ZCX4 0.979 Q3ZCX4 →
P18751 0.979 P18751 →
P52742 0.978 P52742 →
Q8IWY8 0.977 Q8IWY8 →
Q8N9K5 0.977 Q8N9K5 →
A1YFW2 0.977 A1YFW2 →
O75290 0.977 O75290 →
Q02386 0.977 Q02386 →
Q9H7R5 0.977 Q9H7R5 →
Q08DG8 0.977 Q08DG8 →
Q8IVP9 0.976 Q8IVP9 →
A8MQ14 0.976 A8MQ14 →
A2T736 0.976 A2T736 →
P10755 0.976 P10755 →
A0A087WUV0 0.976 A0A087WUV0 →
Q0VGE8 0.976 Q0VGE8 →
A0JNB1 0.976 A0JNB1 →
Q16600 0.976 Q16600 →